S Pica1, G Di Giovine2, M Bollati3, L Testa3, F Bedogni3, A Camporeale2, G Pontone4, D Andreini4, L Monti5, G Gasparini5, L Grancini4, G G Secco6, A Maestroni7, F Ambrogi8, V Milani9, M Lombardi2. 1. Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. Electronic address: silvia.pica@grupposandonato.it. 2. Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. 3. Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. 4. Centro Cardiologico Monzino, IRCCS, Milan, Italy. 5. Istituto Clinico Humanitas, Rozzano, Milan, Italy. 6. A.O.Ss. Antonio e Biagio, Alessandria, Italy. 7. ASTT Valle Olona, Busto Arsizio, Varese, Italy. 8. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 9. Scientific Directorate, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Abstract
BACKGROUND: It is debated whether percutaneous revascularization (PCI) of total coronary chronic occlusion (CTO) is superior to optimal medical therapy (OMT) in improving symptoms, left ventricular (LV) function and major adverse cardiac/cerebrovascular events (MACCE). Furthermore, CTO-PCI is a challenging technique, with lower success rate than in other settings. A systematic analysis of baseline LV function, infarction extent and ischaemic burden to predict response to revascularization has never been performed. PURPOSES: To establish a CMR protocol to identify patients (pts) who can benefit most from CTO-PCI. Myocardial viability/ischaemia retains high biological plausibility as predictors of response to revascularization. Therefore, baseline viability (necrotic tissue extent, response to inotropic stimulation) and ischaemia (perfusion defect, wall motion abnormality during stress) will be studied as potential predictors of mechanical LV segmental improvement and ischaemic burden reduction in CTO territory (primary endpoint), LV remodelling and global function, Seattle Angina Questionnaire, and MACCE improvement (secondary endpoints) in the follow-up. METHODS: Pts with CTO suitable for PCI undergo stress-CMR for viability/ischaemia assessment. Pts with normal LV function undergo adenosine, those with moderately-reduced ejection fraction (EF) and wall motion abnormalities high-dose dobutamine, pts with EF <35% low-dose dobutamine. All pts undergo late gadolinium enhancement and repeat the same scan at 12 ± 3 months, regardless of PCI success or decision for OMT. CONCLUSIONS: A multi-parameter CMR protocol tailored on pts characteristics to study viability/ischaemia could help in identifying responders in terms of LV function, ischaemic burden and clinical outcome among pts suitable for CTO-PCI, improving selection of best candidates to percutaneous revascularization.
BACKGROUND: It is debated whether percutaneous revascularization (PCI) of total coronary chronic occlusion (CTO) is superior to optimal medical therapy (OMT) in improving symptoms, left ventricular (LV) function and major adverse cardiac/cerebrovascular events (MACCE). Furthermore, CTO-PCI is a challenging technique, with lower success rate than in other settings. A systematic analysis of baseline LV function, infarction extent and ischaemic burden to predict response to revascularization has never been performed. PURPOSES: To establish a CMR protocol to identify patients (pts) who can benefit most from CTO-PCI. Myocardial viability/ischaemia retains high biological plausibility as predictors of response to revascularization. Therefore, baseline viability (necrotic tissue extent, response to inotropic stimulation) and ischaemia (perfusion defect, wall motion abnormality during stress) will be studied as potential predictors of mechanical LV segmental improvement and ischaemic burden reduction in CTO territory (primary endpoint), LV remodelling and global function, Seattle Angina Questionnaire, and MACCE improvement (secondary endpoints) in the follow-up. METHODS:Pts with CTO suitable for PCI undergo stress-CMR for viability/ischaemia assessment. Pts with normal LV function undergo adenosine, those with moderately-reduced ejection fraction (EF) and wall motion abnormalities high-dose dobutamine, pts with EF <35% low-dose dobutamine. All pts undergo late gadolinium enhancement and repeat the same scan at 12 ± 3 months, regardless of PCI success or decision for OMT. CONCLUSIONS: A multi-parameter CMR protocol tailored on pts characteristics to study viability/ischaemia could help in identifying responders in terms of LV function, ischaemic burden and clinical outcome among pts suitable for CTO-PCI, improving selection of best candidates to percutaneous revascularization.
Authors: Eleonora Melotti; Marta Belmonte; Carlo Gigante; Vincenzo Mallia; Saima Mushtaq; Edoardo Conte; Danilo Neglia; Gianluca Pontone; Carlos Collet; Jeroen Sonck; Luca Grancini; Antonio L Bartorelli; Daniele Andreini Journal: Front Cardiovasc Med Date: 2022-05-02
Authors: Ka Hou Christien Li; Ka Hei Gabriel Wong; Mengqi Gong; Tong Liu; Guangping Li; Yunlong Xia; Jeffery Ho; Luis Nombela-Franco; Abhishek C Sawant; Simon Eccleshall; Gary Tse; Vassilios S Vassiliou Journal: Curr Atheroscler Rep Date: 2019-08-09 Impact factor: 5.113
Authors: Francesca Baessato; Marco Guglielmo; Giuseppe Muscogiuri; Andrea Baggiano; Laura Fusini; Stefano Scafuri; Mario Babbaro; Rocco Mollace; Ada Collevecchio; Andrea I Guaricci; Gianluca Pontone Journal: Biomed Res Int Date: 2021-01-14 Impact factor: 3.411